Ascendis Pharma ADR (ASND) Stock Price, Quote & News

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clini...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 22 22 44

Website: ascendispharma.com

Address:

Tuborg Boulevard 12, Hellerup, Denmark

CapitalMonk May. 11 at 5:16 PM

$ASND Price: $238.02 (-0.27%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.37% RSI: 48.7 | Momentum: Moderate Volume: -71.6% vs avg Volatility: 2.74% Support: $216.22 | Resistance: $250.27 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

Doozio May. 7 at 6:15 PM

$ASND Thursday 🐑

0 · Reply

Pika_Capital May. 7 at 6:03 PM

$ASND good quarter. Idiots in the morning were selling as usual

2 · Reply

Doozio May. 7 at 2:13 PM

Thursday 🐑 🎁s then da 🧠 can $EXEL and $ASND on FRYday ONTO 🐒🍌🧠⏰♾️

0 · Reply

OpenOutcrier May. 7 at 12:49 PM

$ASND (-4.7% pre) Ascendis lines up $187.5M voucher sale after YUVIWEL approval https://ooc.bz/l/101500

0 · Reply

StocktwitsEarnings May. 7 at 11:52 AM

$ASND Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $10.20 up 745.57% YoY • Reported revenue of $246.6M up 144.27% YoY

0 · Reply

Doozio May. 7 at 3:05 AM

$ENTG 🐑 in da Turing test are already lightening up because SMH stonks are extended as da 🧠 still spreads on the $DLO as the huckleberries still $ASND thru da $$$ ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 30 at 2:50 PM

$XBI $AUPH to $ASND n $EXEL ONTO 🐒🍌🧠⏰♾️

0 · Reply

Hognose Apr. 28 at 8:51 AM

$CAPR $NUVL $ASND $RYTM $ABVX monsters in the making.

0 · Reply

Doozio Apr. 27 at 2:38 PM

$XBI YO $AUPH too $ASND ONTO 🐒🍌🧠⏰♾️

0 · Reply

Ascendis Pharma price target raised to $345 from $342 at Barclays

2026-05-08T10:34:05.000Z - 5 days ago

Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo

2026-05-07T19:27:17.000Z - 5 days ago

Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)

May 7, 2026, 8:00 AM EDT - 6 days ago

Ascendis Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 7:30 AM EDT - 6 days ago

Ascendis Pharma Reports First Quarter 2026 Financial Results

May 6, 2026, 4:01 PM EDT - 6 days ago

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Apr 30, 2026, 4:01 PM EDT - 12 days ago

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Apr 21, 2026, 4:31 PM EDT - 21 days ago

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

2026-04-20T12:12:58.000Z - 23 days ago

Ascendis Pharma announces commencement of trading of shares on Nasdaq

Apr 20, 2026, 8:00 AM EDT - 23 days ago

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

2026-04-16T11:52:18.000Z - 27 days ago

Ascendis Pharma price target raised to $292 from $262 at BofA

2026-04-08T16:07:08.000Z - 5 weeks ago

Ascendis Pharma to list ordinary shares directly on Nasdaq

Apr 8, 2026, 12:00 PM EDT - 5 weeks ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

2026-04-08T12:17:11.000Z - 5 weeks ago

Ascendis Pharma announces new data from COACH trial

Apr 8, 2026, 8:01 AM EDT - 5 weeks ago

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia

2026-04-06T20:05:37.000Z - 5 weeks ago

Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.

Apr 6, 2026, 4:01 PM EDT - 5 weeks ago

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

2026-03-17T12:56:23.000Z - 2 months ago

Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome

Mar 17, 2026, 8:30 AM EDT - 2 months ago

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

2026-03-16T13:27:02.000Z - 2 months ago

Ascendis Pharma assumed with a Buy at Jefferies

2026-03-16T12:17:46.000Z - 2 months ago

Ascendis Pharma announces new data from Navepegritide trial

Mar 16, 2026, 8:00 AM EDT - 2 months ago

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

2026-03-04T20:36:42.000Z - 2 months ago

Ascendis Pharma price target raised to $332 from $325 at Stifel

2026-03-03T14:03:45.000Z - 2 months ago

Ascendis Pharma price target raised to $275 from $250 at RBC Capital

Mar 2, 2026, 11:10 AM EST - 2 months ago

Ascendis Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:43 AM EST - 2 months ago

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 2 months ago

Ascendis Pharma Transcript: FDA announcement

2026-02-27T23:20:20.000Z - 2 months ago

Ascendis Pharma trading resumes

Feb 27, 2026, 6:04 PM EST - 2 months ago

Ascendis wins U.S. approval for therapy for children with dwarfism

2026-02-27T23:00:21.000Z - 2 months ago

Ascendis Pharma announces FDA approval of Yuviwel

Feb 27, 2026, 5:57 PM EST - 2 months ago

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

2026-02-27T21:30:40.000Z - 2 months ago

Ascendis Pharma trading halted, news pending

2026-02-12T14:00:48.000Z - 3 months ago

Ascendis Pharma price target raised to $273 from $240 at Wedbush

2026-02-12T13:43:16.000Z - 3 months ago

Ascendis Pharma price target raised to $262 from $246 at Oppenheimer

2026-02-12T13:28:34.000Z - 3 months ago

Ascendis Pharma price target raised to $325 from $256 at Stifel

Feb 11, 2026, 4:30 PM EST - 3 months ago

Ascendis Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:01 PM EST - 3 months ago

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 4:01 PM EST - 3 months ago

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Jan 12, 2026, 10:30 AM EST - 4 months ago

Ascendis Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:01 PM EST - 4 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:30 PM EST - 4 months ago

Ascendis Pharma Transcript: Study Update

Jan 8, 2026, 4:01 PM EST - 4 months ago

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Jan 5, 2026, 8:30 AM EST - 4 months ago

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 10:37 AM EST - 5 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY INSM MASI NTRA PODD UNH WGS

Dec 8, 2025, 1:54 PM EST - 5 months ago

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ

IYC MPWR GPIQ

Nov 25, 2025, 6:21 PM EST - 6 months ago

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25, 2025, 6:15 PM EST - 6 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Nov 17, 2025, 4:01 PM EST - 6 months ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Nov 12, 2025, 4:30 PM EST - 6 months ago

Ascendis Pharma Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:01 PM EST - 6 months ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:30 AM EST - 6 months ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Nov 5, 2025, 4:01 PM EST - 6 months ago

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

Nov 3, 2025, 4:01 PM EST - 6 months ago

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 8, 2025, 4:01 PM EDT - 7 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Ascendis Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:01 PM EDT - 9 months ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Aug 28, 2025, 4:01 PM EDT - 9 months ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Ascendis Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:01 PM EDT - 10 months ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 28, 2025, 7:00 AM EDT - 10 months ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 14, 2025, 4:01 PM EDT - 10 months ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 7, 2025, 4:01 PM EDT - 11 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Transcript: Study Update

Jun 9, 2025, 7:00 AM EDT - 1 year ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 2, 2025, 8:00 AM EDT - 1 year ago

FDA Accepts TransCon® CNP NDA for Priority Review

May 20, 2025, 6:00 AM EDT - 1 year ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 13, 2025, 4:01 PM EDT - 1 year ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 12, 2025, 4:45 PM EDT - 1 year ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 5, 2025, 8:30 AM EDT - 1 year ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Mar 4, 2025, 11:10 AM EST - 1 year ago

Ascendis Pharma Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:30 PM EST - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q4 2024

Feb 12, 2025, 4:05 PM EST - 1 year ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Feb 12, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:01 PM EST - 1 year ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Jan 13, 2025, 11:15 AM EST - 1 year ago

Ascendis Pharma Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 12, 2025, 5:00 PM EST - 1 year ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

CapitalMonk May. 11 at 5:16 PM

0 · Reply

Doozio May. 7 at 6:15 PM

$ASND Thursday 🐑

0 · Reply

Pika_Capital May. 7 at 6:03 PM

$ASND good quarter. Idiots in the morning were selling as usual

2 · Reply

Doozio May. 7 at 2:13 PM

Thursday 🐑 🎁s then da 🧠 can $EXEL and $ASND on FRYday ONTO 🐒🍌🧠⏰♾️

0 · Reply

OpenOutcrier May. 7 at 12:49 PM

$ASND (-4.7% pre) Ascendis lines up $187.5M voucher sale after YUVIWEL approval https://ooc.bz/l/101500

0 · Reply

StocktwitsEarnings May. 7 at 11:52 AM

$ASND Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $10.20 up 745.57% YoY • Reported revenue of $246.6M up 144.27% YoY

0 · Reply

Doozio May. 7 at 3:05 AM

$ENTG 🐑 in da Turing test are already lightening up because SMH stonks are extended as da 🧠 still spreads on the $DLO as the huckleberries still $ASND thru da $$$ ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 30 at 2:50 PM

$XBI $AUPH to $ASND n $EXEL ONTO 🐒🍌🧠⏰♾️

0 · Reply

Hognose Apr. 28 at 8:51 AM

$CAPR $NUVL $ASND $RYTM $ABVX monsters in the making.

0 · Reply

Doozio Apr. 27 at 2:38 PM

$XBI YO $AUPH too $ASND ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 21 at 12:38 AM

$XBI 🐑 still need to get a 🧠 EDUcation as da huckleberries continue to $ASND thru da $$$$ because it’s TAL good with that BODI ONTO 🐒🍌🧠⏰♾️

1 · Reply

NJgolfer Apr. 18 at 5:25 PM

$ASND another new ATH this past week. Getting into the space where I wonder how much higher it can go this year...

2 · Reply

Doozio Apr. 16 at 3:24 PM

$PPIH Thursday 🐑 🎁s before YO $ASND ONTO 🐒🍌🧠⏰♾️

0 · Reply

SuperGreenToday Apr. 16 at 3:44 AM

$ASND Share Price: $241.71 Contract Selected: Jul 17, 2026 $240 Calls Buy Zone: $17.94 – $22.16 Target Zone: $30.41 – $37.16 Potential Upside: 60% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Doozio Apr. 12 at 2:51 AM

$XBI plenty of ⏰ for da 🐑 to $ASND ONTO ……

1 · Reply

Quantumup Apr. 10 at 4:18 PM

BofA provided its Takeaways from their Inaugural Doctor's Day event [It's a broad research report: many Tx targets; many tickers] -- On $BBIO (Buy; $95) it said: Achondroplasia: oral is the future $ASND $BMRN $TYRA SNY PFE Here's what else BofA had to say in its note to investors: https://x.com/Quantumup1/status/2042637442155462924?s=20

0 · Reply

Doozio Apr. 10 at 1:24 AM

$XBI on FRYday lets walk ENTA da weekend $ASND ing $ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 10 at 1:20 AM

$NBIS da huckleberries are going thru da $$$ for this 🧠leader🐑 as da under da radar 💎 $BWAY bust outta $ASND ing bases 🐒🍌🧠⏰♾️

3 · Reply

NJgolfer Apr. 9 at 6:01 PM

$ASND trying to push through top of channel to new ATHs. 2nd largest portfolio position and long since $21.X 🤩

0 · Reply

WAJeff Apr. 9 at 1:41 PM

Sold my $ASND at $236 again, just range trading this. There’s been a $215-218 floor and this is generally where you dump it.

1 · Reply

NorthStarStats Apr. 8 at 8:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $FRT Score 100, $ANET Score 98, $ENTG Score 98, $STOK Score 98, $ASND Score 98

0 · Reply

CrispDry Apr. 8 at 5:13 PM

$ASND need it to hit 280 range

1 · Reply

Market Cap	14.89B
Revenue (ttm)	814.76M
Net Income (ttm)	-258.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	44.87
Profit Margin	-31.67%
Debt to Equity Ratio	1.84

Volume	879,700
Avg Vol	679,504
Day's Range	N/A - N/A
Shares Out	62.38M
Stochastic %K	57%
Beta	0.41
Analysts	Strong Sell
Price Target	$291.35